Helping patients reclaim a life of possibility
September proved to be an extraordinary month for myeloma advocacy across MPE’s member network. Our members delivered bold, impactful campaigns to raise awareness during Blood Cancer Awareness Month (BCAM) and European Myeloma Day (EMD) on 27 September.
Chimeric antigen receptor (CAR) T-cell therapy is a treatment that uses genetically modified immune cells (T-cells) to treat myeloma. While clinical studies have demonstrated the strong efficacy of CAR T-cell therapies in this disease, many patients experience side effects that can persist for months or years after treatment. To inform myeloma patients and the myeloma…
Last week MPE was in Zagreb for the Autumn EORTC Quality of Life Group meeting, connecting with colleagues working to strengthen the role of quality-of-life data in cancer research. The EORTC is the European Organisation for Research and Treatment of Cancer, a cancer research organisation that brings people together to answer important questions about which…
From September 23-26, Myeloma Patients Europe (MPE) attended the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, Scotland. The IMS Annual Meeting is one of the most important international conferences for myeloma researchers and healthcare professionals, bringing together experts to discuss basic science, preclinical research and clinical developments in myeloma. More than 3,000 people…
On September 17, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of melphalan flufenamide (melflufen, Pepaxti®) to third-line myeloma treatment. The CHMP is the European Medicines Agency’s (EMA) committee responsible for evaluating medicines and making recommendations on whether they should be approved for use…
As the International Myeloma Society (IMS) Annual Meeting is taking place this week, we caught up with myeloma expert Dr. Faith Davies, from NYU Langone, about her expectations for the meeting and why it is important for patient advocacy groups like MPE to attend. What are you looking forward to most about IMS 2026? I…
We want to hear from people living with myeloma and their partners about how myeloma or its treatments have affected intimacy or sexual wellbeing and what information would be useful on this topic. Intimacy and sexual wellbeing can be difficult topics to talk about, but they are an important part of quality of life. Myeloma and…
Myeloma Melodies, an awareness concert for myeloma, returns to Paris on 24 September for an evening of singing, music and fun. The concert is organised by Sarah Tullamore, a professional singer, vocal coach and voice-over artist based in Paris, who is using her voice for a cause close to her heart: raising awareness of myeloma.…